Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

and early efficacy data on the product.

The deal with Roche was a key element in ThromboGenics' corporate strategy, and has allowed the Company to focus on developing the other attractive products in its pipeline, particularly its lead product, microplasmin. The upfront payment from Roche has also provided a significant portion of the funds needed for the microplasmin Phase III program, which will evaluate the drug in a number of back of the eye disease indications.

TB-402 (Anti-Factor VIII) - A Unique, Long-acting Anti-coagulant

ThromboGenics is developing TB-402 in collaboration with BioInvent International. TB-402 is a novel human antibody which partially blocks Factor VIII, an essential blood clotting factor. TB-402 is being developed as an anticoagulant for the treatment and prevention of deep vein thrombosis (DVT) and atrial fibrillation. It is anticipated that TB-402 will be a novel, safe, and affordable anticoagulant, providing extended activity with a single dose, with ease of administration and compliance superior to alternative anticoagulants.

The Phase I interaction studies, which were successfully completed in the second quarter of 2008, have shown that TB-402 has the potential to be a safe and well controlled treatment for diseases where the prevention of blood clots is imperative. As a result of the encouraging results from these studies, TB-402 is expected to begin its Phase II clinical development by the end of 2008.

ThromboGenics will provide a further update when the Company reports its 2008 Full Year Results on 12th March, 2009.
For further information please contact:

ThromboGenics:

Patrik De Haes, CEO, Tel : +32-16-75-13-10,

patrik.dehaes@thrombogenics.com

Chris Buyse, CFO, Tel : +32-16-75-13-10,


'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , 27 avril 2015 /PRNewswire/ ... médicamenteuse spécialisée dans le développement d,une ... soigner les infections bactériennes polypharmacorésistantes potentiellement ... de données prouvant les promesses de ... dans la lutte contre la résistance ...
(Date:4/27/2015)... 27, 2015 SynGen Inc., a company that ... that harvest stem and progenitor cells from umbilical cord ... today that it has added three new members to ... Blood Business Units focus on product commercialization. ... its Vice President and Chief Financial Officer.  Chuck was ...
(Date:4/27/2015)... McKinney, Texas (PRWEB) April 27, 2015 ... products for use in applications such as animal ... fat and oil reduction in wastewater treatment plants ... be an exhibitor at the Texas Commission on ... May 5-6 in Austin, Texas. , The company ...
(Date:4/27/2015)... April 27, 2015 Diasome Pharmaceuticals, ... agreement with Joslin Diabetes Center (“Joslin”) to collaborate ... of Diasome’s novel Hepatocyte Directed Vesicle (“HDV”) targeting ... diabetes. , Located in Boston, Massachusetts, Joslin ... and education organization dedicated to the prevention, treatment ...
Breaking Biology Technology:TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6SynGen Inc. Expands Its Management Team 2DryLet to Showcase Multiple Products at Texas Commission on Environmental Quality Trade Fair and Conference May 5-6 in Austin, Texas 2Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2
... Canopus,BioPharma, Inc. (OTC: CBIA), has confirmed the ... reducing agent and has also demonstrated the,synergistic effect ... and,cetuximab (Erbitux) in two mice lung cancer models., ... stated, "We at,Canopus are encouraged with the discovery ...
... Dominica, June 19 Neuftec,Limited, the proprietor of ... recently issued a claim against Oxonica Energy,Limited, a ... of its,European Patent in the High Court of ... AGM Statement issued by Dr Matthews,(CEO) on 19 ...
... biopharmaceutical industry information on ... ... BioSpace, the world,s,leading online community for the bioscience industry, released ... devices industries in Asia. AsiaBio(TM) features dynamic,informational Hotbed Web pages ...
Cached Biology Technology:CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux). 2Neuftec Responds to a Fundamental Inaccuracy in Oxonica PLC's Regulatory Announcement 2BioSpace Announces New Online Community for Asia 2
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/2/2015)... , April 2, 2015 At its ... Salt Lake City , the American College of ... five new directors to its Board.  Members of the ... ACMG and for forming and advancing its policies and ... genetics profession. "It,s an eventful time in ...
(Date:3/31/2015)... March 31, 2015  Elephant Talk Communications Corp. (NYSE ... provider of Software Defined Network Architecture (ET Software DNA® ... revenue of approximately $20.4 million for the year ended ... million for the year ended December 31, 2013. ... Company had completed its multi-year transition away from its ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... has found that species living together are not forced ... challenging a theory that has held since Darwin,s Origin ... the most diverse bird families in the world, the ... of the processes causing species differences to evolve. ...
... , GAINESVILLE, Fla. --- Using the largest dated evolutionary ... suggests how plants developed traits to withstand low temperatures, ... bigger threat than initially thought to plants and global ... the journal Nature and co-authored by University ...
... scientists, chemical engineers and physicists from the University of Pennsylvania ... crystals as a medium for assembling structures. In their ... in the repeating patterns found in liquid crystals, in nanoscale ... pattern out of an even simpler template: a three-dimensional array ...
Cached Biology News:'Be different or die' does not drive evolution 2'Be different or die' does not drive evolution 3Study: Some plants may not adapt quickly to future climate change 2Study: Some plants may not adapt quickly to future climate change 3Penn researchers grow liquid crystal 'flowers' that can be used as lenses 2Penn researchers grow liquid crystal 'flowers' that can be used as lenses 3
PKC (pSer345), phospho-specific...
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
Rabbit polyclonal to Streptococcus Enterotoxin C ( Abpromise for all tested applications)....
... 100 g monoclonal antibody which can ... V from heart mitochondria. Also included are ... control immunocapture. The Complex V immunocapture kit ... (E.C. 3.6.3.14) from small amounts of tissue. ...
Biology Products: